Clinical Trials · NCT00216398

Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR

Name: Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 4Octreotide Lanreotide

Phase: Phase 4
Recruitment status: Completed
Sponsor: Ipsen
Enrollment: 8
Start date: Jun 2004
Locations: 1 site, Australia
Primary endpoint: The percentage of patients with GH control (<5.0 mU.L) and normalised IGF-1 at week 44 compared to the baseline (Week 0) visit.

View Octreotide compound reference